PDF(Pubmed)
Abstract：
UNASSIGNED: This meta-analysis evaluates the comparative diagnostic efficacy of 68Ga-prostate-specific membrane antigen-11 PET (68Ga-PSMA-11 PET) and multiparametric MRI (mpMRI) for the initial lymph node staging of prostate cancer.
UNASSIGNED: We searched PubMed and Embase databases through October 2023 for studies that provide a head-to-head comparison of 68Ga-PSMA-11 PET and mpMRI, using pelvic lymph node dissection as the gold standard. We assessed sensitivity and specificity using the DerSimonian and Laird method, with variance stabilization via the Freeman-Tukey double inverse sine transformation. The quality of included studies was evaluated using the Quality Assessment of Diagnostic Performance Studies (QUADAS-2) tool.
UNASSIGNED: The meta-analysis incorporated 13 articles, involving a total of 1,527 patients. 68Ga-PSMA-11 PET demonstrated an overall sensitivity of 0.73 (95% CI: 0.51-0.91) and a specificity of 0.94 (95% CI: 0.88-0.99). In comparison, mpMRI showed a sensitivity of 0.49 (95% CI: 0.30-0.68) and a specificity of 0.94 (95% CI: 0.88-0.99). Although 68Ga-PSMA-11 PET appeared to be more sensitive than mpMRI, the differences in sensitivity (p = 0.11) and specificity (p = 0.47) were not statistically significant.
UNASSIGNED: Our findings indicated that 68Ga-PSMA-11 PET and mpMRI exhibit similar sensitivity and specificity in the diagnosis of initial lymph node staging of prostate cancer. However, given that most included studies were retrospective, further prospective studies with larger sample sizes are essential to validate these results.
UNASSIGNED: PROSPERO code is CRD42023495266.
UNASSIGNED: We searched PubMed and Embase databases through October 2023 for studies that provide a head-to-head comparison of 68Ga-PSMA-11 PET and mpMRI, using pelvic lymph node dissection as the gold standard. We assessed sensitivity and specificity using the DerSimonian and Laird method, with variance stabilization via the Freeman-Tukey double inverse sine transformation. The quality of included studies was evaluated using the Quality Assessment of Diagnostic Performance Studies (QUADAS-2) tool.
UNASSIGNED: The meta-analysis incorporated 13 articles, involving a total of 1,527 patients. 68Ga-PSMA-11 PET demonstrated an overall sensitivity of 0.73 (95% CI: 0.51-0.91) and a specificity of 0.94 (95% CI: 0.88-0.99). In comparison, mpMRI showed a sensitivity of 0.49 (95% CI: 0.30-0.68) and a specificity of 0.94 (95% CI: 0.88-0.99). Although 68Ga-PSMA-11 PET appeared to be more sensitive than mpMRI, the differences in sensitivity (p = 0.11) and specificity (p = 0.47) were not statistically significant.
UNASSIGNED: Our findings indicated that 68Ga-PSMA-11 PET and mpMRI exhibit similar sensitivity and specificity in the diagnosis of initial lymph node staging of prostate cancer. However, given that most included studies were retrospective, further prospective studies with larger sample sizes are essential to validate these results.
UNASSIGNED: PROSPERO code is CRD42023495266.
摘要：
■该荟萃分析评估了68Ga-前列腺特异性膜抗原-11PET（68Ga-PSMA-11PET）和多参数MRI（mpMRI）对初始淋巴结分期的比较诊断功效前列腺癌。
■我们在2023年10月之前搜索了PubMed和Embase数据库，以进行对68Ga-PSMA-11PET和mpMRI的头对头比较的研究，以盆腔淋巴结清扫术为金标准。我们使用DerSimonian和Laird方法评估敏感性和特异性，通过Freeman-Tukey双反正弦变换进行方差稳定。使用诊断性能研究质量评估（QUADAS-2）工具评估纳入研究的质量。
■荟萃分析纳入了13篇文章，共涉及1,527名患者。68Ga-PSMA-11PET显示0.73(95%CI:0.51-0.91)的总体灵敏度和0.94(95%CI:0.88-0.99)的特异性。相比之下,MPMRI的敏感性为0.49(95%CI:0.30-0.68),特异性为0.94(95%CI:0.88-0.99).尽管68Ga-PSMA-11PET似乎比mpMRI更敏感，敏感性(p=0.11)和特异性(p=0.47)差异无统计学意义.
■我们的发现表明，68Ga-PSMA-11PET和mpMRI在诊断前列腺癌的初始淋巴结分期方面表现出相似的敏感性和特异性。然而,鉴于大多数纳入研究是回顾性的，更大样本量的进一步前瞻性研究对于验证这些结果至关重要.
■PROSPERO代码为CRD42023495266。
■我们在2023年10月之前搜索了PubMed和Embase数据库，以进行对68Ga-PSMA-11PET和mpMRI的头对头比较的研究，以盆腔淋巴结清扫术为金标准。我们使用DerSimonian和Laird方法评估敏感性和特异性，通过Freeman-Tukey双反正弦变换进行方差稳定。使用诊断性能研究质量评估（QUADAS-2）工具评估纳入研究的质量。
■荟萃分析纳入了13篇文章，共涉及1,527名患者。68Ga-PSMA-11PET显示0.73(95%CI:0.51-0.91)的总体灵敏度和0.94(95%CI:0.88-0.99)的特异性。相比之下,MPMRI的敏感性为0.49(95%CI:0.30-0.68),特异性为0.94(95%CI:0.88-0.99).尽管68Ga-PSMA-11PET似乎比mpMRI更敏感，敏感性(p=0.11)和特异性(p=0.47)差异无统计学意义.
■我们的发现表明，68Ga-PSMA-11PET和mpMRI在诊断前列腺癌的初始淋巴结分期方面表现出相似的敏感性和特异性。然而,鉴于大多数纳入研究是回顾性的，更大样本量的进一步前瞻性研究对于验证这些结果至关重要.
■PROSPERO代码为CRD42023495266。
